Lamiaa Zidan1,2, Amir Iravani3,4, Grace Kong3,4, Tim Akhurst3,4, Michael Michael4,5, Rodney J Hicks3,4. 1. Cancer imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. lamiazidan@gmail.com. 2. Clinical Oncology and Nuclear Medicine department, Cairo University, Cairo, Egypt. lamiazidan@gmail.com. 3. Cancer imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. 4. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia. 5. Division of Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Abstract
PURPOSE: This study aimed to analyse the molecular imaging (MI) phenotype of typical carcinoid (TC) and atypical carcinoid (AC) by 68Ga-DOTATATE (GaTATE) and 18F-FDG (FDG) PET/CT with the emphasis on its potential theranostic implications for peptide receptor radionuclide therapy (PRRT). METHODS: Retrospective review of patients with biopsy-proven TC or AC undergoing both GaTATE and FDG PET/CT at presentation. Based on correlative CT or MRI, positive lesions on either scan were defined by uptake above liver parenchyma. Per patient MI phenotypic pattern was classified as score 1, if all lesions were negative on both scans; score 2, if all were GaTATE positive/FDG negative; score 3, if all lesions were GaTATE positive but some or all were also FDG positive and score 4, if there were any GaTATE negative/FDG positive lesions. Scores 1 and 4 were deemed unsuitable for PRRT. RESULTS: Of 56 patients (median age 66.5 years, 32 female), 22 had TC, and 34 had AC. Distant metastases were seen in 32% of TC and 94% of AC. At a median follow-up of 37 months for TC and 38 months for AC, 100% and 63% were alive, respectively. Median OS for AC was 56 months (95% CI 43, not reached [NR]), and TC was NR. On inter-patient dual-tracer analysis, scores 1, 2, 3 and 4 were 23%, 18%, 36% and 23% in TC and 3%, 15%, 32% and 50% in AC, respectively. In 16 patients (score 2, N = 3; score 3, N = 12; score 4, N = 1) who were treated with PRRT, disease control rate at 3 months and OS were, 85% and 54.6 months (95% CI 44-70), respectively. CONCLUSIONS: TC and AC showed a wide inter-patient phenotypic heterogeneity on GaTATE and FDG with around half of patients (46% TC and 53% AC) having an unsuitable phenotype for PRRT. Dual-tracer MI phenotype can be used to select the most suitable patients for PRRT.
PURPOSE: This study aimed to analyse the molecular imaging (MI) phenotype of typical carcinoid (TC) and atypical carcinoid (AC) by 68Ga-DOTATATE (GaTATE) and 18F-FDG (FDG) PET/CT with the emphasis on its potential theranostic implications for peptide receptor radionuclide therapy (PRRT). METHODS: Retrospective review of patients with biopsy-proven TC or AC undergoing both GaTATE and FDG PET/CT at presentation. Based on correlative CT or MRI, positive lesions on either scan were defined by uptake above liver parenchyma. Per patient MI phenotypic pattern was classified as score 1, if all lesions were negative on both scans; score 2, if all were GaTATE positive/FDG negative; score 3, if all lesions were GaTATE positive but some or all were also FDG positive and score 4, if there were any GaTATE negative/FDG positive lesions. Scores 1 and 4 were deemed unsuitable for PRRT. RESULTS: Of 56 patients (median age 66.5 years, 32 female), 22 had TC, and 34 had AC. Distant metastases were seen in 32% of TC and 94% of AC. At a median follow-up of 37 months for TC and 38 months for AC, 100% and 63% were alive, respectively. Median OS for AC was 56 months (95% CI 43, not reached [NR]), and TC was NR. On inter-patient dual-tracer analysis, scores 1, 2, 3 and 4 were 23%, 18%, 36% and 23% in TC and 3%, 15%, 32% and 50% in AC, respectively. In 16 patients (score 2, N = 3; score 3, N = 12; score 4, N = 1) who were treated with PRRT, disease control rate at 3 months and OS were, 85% and 54.6 months (95% CI 44-70), respectively. CONCLUSIONS:TC and AC showed a wide inter-patient phenotypic heterogeneity on GaTATE and FDG with around half of patients (46% TC and 53% AC) having an unsuitable phenotype for PRRT. Dual-tracer MI phenotype can be used to select the most suitable patients for PRRT.
Authors: Mathias Gugger; Elisabeth Burckhardt; Andreas Kappeler; Hans Hirsiger; Jean A Laissue; Luca Mazzucchelli Journal: J Pathol Date: 2002-04 Impact factor: 7.996
Authors: David L Chan; Gary A Ulaner; David Pattison; David Wyld; Rahul Ladwa; Julian Kirchner; Bob T Li; W Victoria Lai; Nick Pavlakis; Paul J Roach; Dale L Bailey Journal: J Nucl Med Date: 2021-02-12 Impact factor: 10.057
Authors: Wolfgang M Thaiss; Sergios Gatidis; Tina Sartorius; Jürgen Machann; Andreas Peter; Thomas K Eigentler; Konstantin Nikolaou; Bernd J Pichler; Manfred Kneilling Journal: Cancer Immunol Immunother Date: 2020-11-01 Impact factor: 6.968
Authors: Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Ahmed Ebada Salem; Richard H Wiggins; John M Hoffman; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-06-08 Impact factor: 6.575
Authors: Philippe Thuillier; Virginia Liberini; Osvaldo Rampado; Elena Gallio; Bruno De Santi; Francesco Ceci; Jasna Metovic; Mauro Papotti; Marco Volante; Filippo Molinari; Désirée Deandreis Journal: Biomedicines Date: 2021-03-10
Authors: Leonie Beyer; Astrid Gosewisch; Simon Lindner; Friederike Völter; Lena M Mittlmeier; Reinhold Tiling; Matthias Brendel; Clemens C Cyran; Marcus Unterrainer; Johannes Rübenthaler; Christoph J Auernhammer; Christine Spitzweg; Guido Böning; F J Gildehaus; Klaus Jurkschat; Carmen Wängler; Björn Wängler; Ralf Schirrmacher; Vera Wenter; Andrei Todica; Peter Bartenstein; Harun Ilhan Journal: Eur J Nucl Med Mol Imaging Date: 2021-04-29 Impact factor: 9.236